Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 on X: "The evolution of MM therapies, if one only focuses on MRD (10⁻⁵). Lots of caveats, and for older studies some guesses based on the CR rate (
![Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study - The Lancet Oncology Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study - The Lancet Oncology](https://www.thelancet.com/cms/asset/97a36e19-fdfd-4031-843c-70efbe4cf5da/gr1.jpg)
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study - The Lancet Oncology
![COVID19 Vaccine Preface - Why Do People Beat the Average Myeloma Life Expectancy Prognosis? Or How To Improve Your Multiple Myeloma Survival Rate! - Multiple Myeloma - Survival Rate Statistics by Hospital COVID19 Vaccine Preface - Why Do People Beat the Average Myeloma Life Expectancy Prognosis? Or How To Improve Your Multiple Myeloma Survival Rate! - Multiple Myeloma - Survival Rate Statistics by Hospital](http://myelomasurvival.com/uploads/3/4/4/8/34484049/published/msmart2020.jpg?1601233051)